Labopharm Inc., of Laval, Quebec, updated its strategic review process and, with the aim of preserving capital, entered discussions for restructuring its joint venture agreement with Gruppo Angelini SpA, of Rome, for commercializing depression drug Oleptro (trazodone hydrochloride extended-release tablets) in the U.S. Labopharm also is reviewing Oleptro for all territories outside the U.S.